CRISPR-Cas base editing altered HTT RNA splicing and reduced toxic huntingtin fragments in a mouse model of Huntington’s disease. Treated mice showed...

A hybrid-vesicle delivery platform helped CRISPR-Cas9 selectively kill the caries-associated bacterium Streptococcus mutans. The treatment remodelled...

Researchers have engineered probiotic bacteria to produce CRISPR-Cas9 and edit the ROS-generating NOX2/gp91phox target in mouse intestinal cells. The...

Epicrispr Biotechnologies has completed enrolment and dose escalation in the first-in-human trial of EPI-321, an epigenetic CRISPR-based therapy for...

Some of the best links we picked up around the internet

Beam Therapeutics has received U.S. FDA clearance of its Investigational New Drug (IND) application for BEAM-304, an in vivo base-editing therapy for...

A single intravenous dose of Intellia Therapeutics’ in vivo CRISPR-Cas9 therapy lonvoguran ziclumeran (lonvo-z) reduced monthly hereditary angioedema...

When clinicians at the Children’s Hospital of Philadelphia (CHOP) treated baby KJ – born with a rare, often-fatal urea-cycle disorder – with a CRISPR...